We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+20.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$215M
AUM Growth
+$41.5M
Cap. Flow
+$31.8M
Cap. Flow %
14.78%
Top 10 Hldgs %
55.52%
Holding
68
New
22
Increased
11
Reduced
19
Closed
11

Top Buys

Rank Stock Value
1
QCP
Quality Care Properties, Inc.
QCP
+$11.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.2M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$8.59M
4
GSK icon
GSK
GSK
+$8.44M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$6.04M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$14.1M
2
EHTH icon
eHealth
EHTH
+$4.18M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$4.01M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$2.62M
5
PBYI icon
Puma Biotechnology
PBYI
+$2.38M

Sector Composition

Rank Sector Weight
1 Healthcare 75.31%
2 Real Estate 9.99%
3 Miscellaneous 7.87%
4 Industrials 6.33%
5 Financials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
51
Neurogene
NGNE
$732M
$450K 0.21%
1,599
+599
+60% +$165K
ISEE
52
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$409K 0.19%
149,100
– –
EVHC
53
DELISTED
Envision Healthcare Holdings Inc
EVHC
$366K 0.17%
9,520
-70,000
-88% -$2.62M
MDXG icon
54
CALL
MiMedx Group
MDXG
$656M
$335K 0.16%
+48,000
New +$559K
SPNE
55
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$313K 0.15%
30,899
– –
DERM
56
DELISTED
Dermira, Inc.
DERM
$160K 0.07%
+20,018
New +$436K
QTNT
57
DELISTED
Quotient Limited Ordinary Shares
QTNT
$49.5K 0.02%
263
– –
AXGN icon
58
Axogen
AXGN
$2.77B
– –
-57,723
Closed -$1.63M
CDTX
59
DELISTED
Cidara Therapeutics
CDTX
– –
-2,500
Closed -$340K
PCRX icon
60
Pacira BioSciences
PCRX
$1.03B
– –
-25,100
Closed -$1.15M
VREX icon
61
Varex Imaging
VREX
$780M
– –
-20,700
Closed -$832K
ZBH icon
62
Zimmer Biomet
ZBH
$19.2B
– –
-14,420
Closed -$1.69M
CLVS
63
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-16,397
Closed -$1.11M
SRRA
64
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-1,675
Closed -$250K
ALXN
65
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-33,500
Closed -$4.01M
CIVI
66
DELISTED
Civitas Solutions, Inc.
CIVI
– –
-23,529
Closed -$402K
ARDM
67
DELISTED
Aradigm Corp Common Stock
ARDM
– –
-52,115
Closed -$349K
IVTY
68
DELISTED
Invuity, Inc
IVTY
– –
-45,000
Closed -$279K
1 2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Eversept Partners held 68 positions worth $215M, up 24% from $174M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $31.8M of net new capital in Q1 2018, opening 22 new positions and adding to 11 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 78,893 shares worth $9.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 75% a quarter earlier, followed by Real Estate and Miscellaneous.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $14.1M trimmed.

  • Eversept Partners's largest Q1 2018 buy was Alnylam Pharmaceuticals: 78,893 shares worth $9.4M.
  • Eversept Partners added most to Quality Care Properties, Inc. in Q1 2018, an estimated $11.7M increase.
  • Eversept Partners's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $14.1M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q1 2018, selling an estimated $4.01M.
  • Eversept Partners's ten largest holdings make up 56% of its $215M portfolio in Q1 2018.
  • Eversept Partners opened 22 new positions and closed 11 in Q1 2018.
  • Eversept Partners's portfolio value rose 24% quarter-over-quarter to $215M.

Based on Eversept Partners's 13F filing for Q1 2018, filed 14 May 2018.